☰

Elizabeth J. Rahn, Ph.D., M.S.

Affiliations: 
Neurobiology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Pain, Cannabinoids, Neuropsychopharmacology, Epigenetics
Google:
"Elizabeth Rahn"
Mean distance: 13.78 (cluster 19)
 		SNBCP
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
M. Christopher Newland research assistant 2004-2005 Auburn University
Andrea G. Hohmann grad student 2005-2010 Neuroscience and Behavior Program, University of Georgia
J. David Sweatt post-doc 2011- UAB

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Danila MI, Allison JJ, Goins KV, et al. (2021) Development of a multi-component intervention to promote participation of Black and Latinx individuals in biomedical research. Journal of Clinical and Translational Science. 5: e134
Lawrence CE, Dunkel L, McEver M, et al. (2020) A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. Journal of Clinical and Translational Science. 4: 345-353
Kennedy AJ, Rahn EJ, Paulukaitis BS, et al. (2016) Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Reports
Rahn EJ, Deng L, Thakur GA, et al. (2014) Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27
Rahn EJ, Thakur GA, Wood JA, et al. (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502
Rahn EJ, Zvonok AM, Makriyannis A, et al. (2010) Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57
Rahn EJ, Hohmann AG. (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 713-37
Rahn EJ, Zvonok AM, Thakur GA, et al. (2008) Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91
Rahn EJ, Makriyannis A, Hohmann AG. (2007) Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77
Rahn E, Hohmann A. (2007) 289 CANNABINOIDS SUPPRESS CHEMOTHERAPY-EVOKED PAINFUL PERIPHERAL NEUROPATHY THROUGH SPINAL SITES OF ACTION European Journal of Pain. 11: S128-S128
See more...